The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in participants with systemic lupus erythematosus
Aged 18-75 years;
Diagnosed with SLE for ≥12 weeks prior to screening, met the 2019 ACR/EULAR diagnostic criteria for SLE screening period;
SELENA-SLEDAI ≥8 at screening;
Positive immunological markers within 12 months prior to baseline;
Severe active or unstable lupus-related neuropsychiatric disorders;
Combined with active infections, malignant tumors, or other autoimmune diseases;
Catastrophic antiphospholipid syndrome;
severe lupus nephritis;